Immunotherapy trial results transforming care for rare skin cancer
April 19, 2016
| By Susan Keown / Fred Hutch News Service
With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.
From cancer vaccines to engineered T cells, experts weigh in on the big unknowns
March 18, 2016
| by Susan Keown / Fred Hutch News Service
Fred Hutch immunotherapy experts share their perspectives on a few of the big questions in cancer immunotherapy research — and the steps that they and their colleagues are taking to answer them as quickly as they can.
Immune-boosting therapy shows promise for advanced Merkel cell carcinoma
Oct. 6, 2015
| By Dr. Rachel Tompa / Fred Hutch News Service
Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.